Patents by Inventor Melissa B. Brennan

Melissa B. Brennan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for measuring ubiquitin carboxy—terminal hydrolase L1 levels in blood
    Patent number: 12123883
    Abstract: Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: October 22, 2024
    Assignee: ABBOTT LABORATORIES
    Inventors: Gangamani S. Beligere, Melissa B. Brennan, Jessica Grieshaber, David Pacenti, Saul A. Datwyler, John M. Ramp
  • METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-B-CORONAVIRUS ANTIBODY IN A SAMPLE
    Publication number: 20230258638
    Abstract: Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of ?-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-?-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject.
    Type: Application
    Filed: October 12, 2022
    Publication date: August 17, 2023
    Inventors: A. Scott Muerhoff, John C. Prostko, James L. Stewart, Mary A. RODGERS, Gavin A. CLOHERTY, James Hartnett, Jeff Moore, Kathy Otis, Alak Kar, Bailin Tu, Bryan Tieman, Carolyn Strobel, David Hawksworth, Robert Ziemann, Zhihong Lin, Chris Marohnic, Peter Wiebe, Todd Meyer, Weijie Jiao, Gangamani S. Beligere, Saminathan X. Muthusamy, Jessica L. Grieshaber, Sandra K. Pearce, Edwin C. Frias, Russell E. Taylor, Kelly Coller, Yangrong E. Zhang, Thomas T. Biegalski, David J. Daghfal, Claudio Galli, Sergey Y. Tetin, Qiaoqiao Ruan, Patrick MacDonald, Michael S. Cassidy, Mary E. Gardiner, Mary Ann P. Palafox, Matthew S. Matias, Melissa B. Brennan, Philip W. Schultz, Beth C. Trudeau
  • METHODS FOR MEASURING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 LEVELS IN BLOOD
    Publication number: 20220128579
    Abstract: Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
    Type: Application
    Filed: September 30, 2021
    Publication date: April 28, 2022
    Inventors: Gangamani S. Beligere, Melissa B. Brennan, Jessica Grieshaber, David Pacenti, Saul A. Datwyler, John M. Ramp
  • Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
    Patent number: 11169159
    Abstract: Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 9, 2021
    Assignee: Abbott Laboratories
    Inventors: Gangamani S. Beligere, Melissa B. Brennan, Jessica Grieshaber, David Pacenti, Saul A. Datwyler, John M. Ramp
  • METHODS FOR MEASURING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 LEVELS IN BLOOD
    Publication number: 20190033327
    Abstract: Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 31, 2019
    Inventors: Gangamani S. Beligere, Melissa B. Brennan, Jessica Grieshaber, David Pacenti, Saul A. Datwyler, John M. Ramp